Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Dec;31(12):1664-1678.
doi: 10.1016/j.annonc.2020.09.006. Epub 2020 Sep 22.

Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†

M Lambertini  1 , F A Peccatori  2 , I Demeestere  3 , F Amant  4 , C Wyns  5 , J-B Stukenborg  6 , S Paluch-Shimon  7 , M J Halaska  8 , C Uzan  9 , J Meissner  10 , M von Wolff  11 , R A Anderson  12 , K Jordan  10 ; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Affiliations
Free article
Practice Guideline

Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†

M Lambertini et al. Ann Oncol. 2020 Dec.
Free article
No abstract available

Keywords: Clinical Practice Guidelines; cancer; fertility; pregnancy.

PubMed Disclaimer

Conflict of interest statement

Disclosure ML reported consultancy or advisory role and speaker's honoraria from Roche, Theramex, Takeda, Pfizer, Novartis and Lilly; FAP reported consultancy or advisory role and speaker's honoraria from Roche, Clovis, Takeda and Ipsen; ID reported advisory role and speaker's honoraria from Roche and Novartis; FA is a senior researcher for the Research Fund Flanders (FWO); SPS reported consultancy or advisory role and speaker's honoraria from Roche, Novartis, Pfizer and AstraZeneca. RAA reported consultancy and research support from Roche Diagnostics, Ferring Pharmaceuticals, IBSA and Merck; KJ reported speaker's honoraria or advisory role from Merck Sharp and Dohme, Merck, Amgen, Hexal, Riemser, Helsinn, Kreussler, Voluntis, Pfizer, POMME-med, PharmaMar, art-tempi and priME Oncology. The remaining authors have declared no potential conflicts of interest.

Publication types